News & analysis
Times are shown in GMT+11, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.Opthea Ltd, formerly Circadian Technologies Ltd develops and commercializes therapies for cancer, eye diseases, and others. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets.
Latest OPT News